Impact of Enterococcus Faecalis KY072975 Supplementation as Probiotic on High Cholesterol Level In-vivo

Elevated blood cholesterol levels are considered a significant and potentially fatal condition in humans. The current study sought to elucidate the effect of the Lactic acid bacteria (LAB) strain Enterococcus faecalisW7 as a probiotic on elevated cholesterol levels in hamsters. Ten male hamsters aged after acclimatization were randomly assigned to the control group (CG) and experimental groups high-fat group (HFG). Hamsters in CG were fed chow pellets only, while those in HFC were fed chow pellets supplemented with 40% beef tallow and 1% cholesterol for 30 days. After achieving obesity, hamsters in HFG were fed the same diet with isolate E. faecalis W7 lypholized powder (390 mg/kg BW/day) with high viable counts of LAB (4 × 1012 CFU/g) orally for two weeks (HFG+E.f. W7). The results demonstrated a significant drop in body weight in the HFG+E.f. W7 group (41.78%) compared to HFG rats (46.82%) and CG rats. The HFG+E.f. W7 group had significantly lower total cholesterol, low denisty lipoprotein (LDL), and triglyceride levels (p<0.05) compared to the HFG and CG groups. The HFG+E.f. W7 group showed substantial decreases (p<0.05) in liver enzymes SGPT and SGOT compared to the HFG and CG groups. While comparing rats in the HFG and CG groups, there was a small drop in HDL levels of 41mg/dL. In conclusion, using E. faecalisW7 per os as a probiotic could be a potential intervention to reverse the adverse effects of excessive cholesterol levels in the blood.